Drug Update · Rare Disease

FDA Approves KYGEVVI for TK2d: Cuts Death Risk 86%

July 22, 2026

Drug

doxecitine and doxribtimine (KYGEVVI)

Indication

Thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with age of symptom onset on or before 12 years [5]

Primary efficacy result

Reduced overall risk of death by approximately 86% (95% CI: 61%, 96%) versus matched untreated external control [12]

Approval date

FDA original approval date: 2025-11-03; Label effective date: 2025-11-10 [12]

Recommended maintenance dose

800 mg/kg/day (consisting of 400 mg doxecitine and 400 mg doxribtimine) administered in 3 equally divided doses with food [5][12]

Clinical Perspective

Clinicians treating patients with TK2d and patients (adults and pediatric patients with an age of symptom onset on or before 12 years) should note that KYGEVVI is now an FDA-approved oral pyrimidine nucleoside replacement therapy for TK2d ^[3]^[4]. The approval is supported by pooled clinical data showing approximately an 86% reduction in the risk of death from treatment start versus a matched untreated external control group, with median treatment durations of 4 years in treated patients ^[4]. What are the longer-term safety outcomes and optimal monitoring intervals for liver tests and gastrointestinal adverse events with prolonged KYGEVVI use beyond the reported follow-up periods?

Editorial Team · Rare Disease

KYGEVVI (doxecitine and doxribtimine) was approved by the FDA on 2025-11-03 for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years ^[4]^[3]. The approval was based on pooled data including a prospective single-arm study (Trial 1) and retrospective cohorts showing that treatment reduced the overall risk of death from treatment start by approximately 86% (95% CI: 61%, 96%) versus a matched untreated external control group ^[4].

Clinical Context

KYGEVVI is a fixed combination of two pyrimidine nucleosides, doxecitine (deoxycytidine, dC) and doxribtimine (deoxythymidine, dT), developed for patients with thymidine kinase 2 deficiency (TK2d) ^[3]^[1]. TK2d is described in the sources as an ultra-rare mitochondrial DNA depletion and multiple deletion syndrome with progressive muscle weakness and premature death ^[1]. KYGEVVI is supplied as a powder for oral solution and is packaged by UCB, Inc. ^[3]. The mechanism of action provided in the regulatory materials is incorporation of administered deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA to restore mitochondrial DNA copy number in TK2d mutant mice ^[4].

Key Findings

KYGEVVI reduced the risk of death by approximately 86% (95% CI: 61%, 96%) from treatment start versus a matched untreated external control group in the pooled analysis of treated patients with TK2d (age of symptom onset ≤12 years) ^[4].

The efficacy assessment included one prospective, open-label, single-arm trial (Trial 1, NCT03845712) and retrospective chart-review cohorts plus expanded-access data; treated patients (n=78 matched pairs for survival analysis) were compared 1:1 to matched untreated patients by age of symptom onset category, with matching procedures and time-alignment described in the regulatory submission ^[4]. Median treatment duration reported across treated patients was 4 years and the median dose received in treated patients was 762 mg/kg/day (range: 260 to 800 mg/kg/day) ^[4]. Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

The most common adverse reactions (incidence ≥5%) reported in the prescribing information are diarrhea, abdominal pain (including abdominal pain upper), vomiting, alanine aminotransferase increased (ALT), and aspartate aminotransferase increased (AST) ^[3].
In the Phase 1 pharmacokinetic and tolerability studies in healthy adults, the most frequent study-drug-related adverse events were diarrhea (n = 4/29, 14%) and dizziness (n = 3/29, 10%) ^[1].
The label notes reports of diarrhea and vomiting that led to hospitalization, dose reduction, and permanent discontinuation in some patients treated with KYGEVVI ^[2].
Elevated liver transaminase levels were reported in patients treated with KYGEVVI; in Study 1 two patients permanently discontinued treatment upon recurrence of elevated liver enzymes after a rechallenge at a reduced dose ^[2].

Study Design

The primary efficacy evidence for approval included Trial 1 (NCT03845712), a prospective, open-label, single-arm study in 47 patients with genetically confirmed TK2d previously treated with pyrimidine nucleosides, plus two retrospective chart-review cohorts (Study 1 and Study 2) and expanded-access program data ^[4]. Efficacy for survival was assessed by matching treated patients 1:1 to untreated external-control patients by age of symptom onset (≤2 years or >2 to ≤12 years), yielding 78 matched pairs for the survival analysis; hazard-ratio estimates were derived using a Cox proportional hazards model with Firth correction and strata for matched pairs ^[4]. Details of dosing, preparation, and administration (including use of the ZX2000 administration kit) are provided in the approved labeling ^[3]^[4].

FAQ

Q1 What is KYGEVVI (doxecitine and doxribtimine) approved for?

KYGEVVI is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. The indication is stated in the approved prescribing information and DailyMed highlights. The approval covers both adults and pediatric patients meeting the age-of-onset criterion.

Q2 How does KYGEVVI work?

KYGEVVI is a fixed 1:1 mixture of two pyrimidine nucleosides (deoxycytidine and deoxythymidine). Administration is intended to incorporate these pyrimidine nucleosides into skeletal muscle mitochondrial DNA and thereby restore mitochondrial DNA copy number, an effect demonstrated in TK2-deficient mutant mice as described in the regulatory materials.

Q3 What is the recommended dose of KYGEVVI?

The labeling provides weight-based recommended dosage levels titrated by tolerability: a Starting dose of 260 mg/kg/day (130 mg doxecitine + 130 mg doxribtimine), an Intermediate dose of 520 mg/kg/day (260 mg + 260 mg), and a Maintenance dose of 800 mg/kg/day (400 mg + 400 mg), administered orally in 3 equally divided doses with food; titration is recommended after a minimum of 2 weeks at each level. Use KYGEVVI only with the ZX2000 administration kit and obtain baseline ALT, AST, and total bilirubin prior to initiation. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects of KYGEVVI?

The most commonly reported adverse reactions (incidence ≥5%) in the prescribing information are diarrhea, abdominal pain (including upper abdominal pain), vomiting, alanine aminotransferase increased (ALT), and aspartate aminotransferase increased (AST). Phase 1 healthy volunteer studies reported diarrhea in 4 of 29 participants (14%) and dizziness in 3 of 29 participants (10%). The labeling also documents diarrhea and vomiting that have led to hospitalization, dose reduction, or permanent discontinuation in some patients and reports of elevated liver transaminases with treatment interruption or discontinuation in affected patients.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves KYGEVVI for TK2d: Cuts Death Risk 86%

FDA Approves KYGEVVI for TK2d: Cuts Death Risk 86%

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Rare Disease in your inbox.

Related Clinical Updates

FDA Approves marnetegragene autotemcel for LAD-I: 100% HSCT-free

FDA Approves Elamipretide for Barth Syndrome: 63 N Knee Strength Gain

DTX401 Achieved 68% Cornstarch Reduction in Adults With GSDIa

Verified HCP Portal